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Introduction
The allogeneic stem cell transplantation (alloSCT) 
activity in Europe is continuously increasing. On 
the one hand, indications become more restricted 
as molecular techniques enable to identify subsets 
of patients who are more likely to benefit from 
the graft-versus-tumor (GVT) effect. On the other 
hand, the introduction in the mid-nineties of non-
myeloablative alloSCT (NM-alloSCT) has allowed 
to expand the indications to more elderly patients 
or those with comorbidities. Despite improvements 
in supportive care, alloSCT remains a potentially 
dangerous treatment option because of the risk of 
infections and graft-versus-host disease. Many cen-
ters and/or collaborative groups are still initiating 
studies aiming at improving conditioning regimens 
and posttransplant immunosuppression as well as 
the use of donor lymphocyte infusions or other cel-
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Academic clinical trials run by the 
Transplant Committee of the Belgian 
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Belgian transplantation clinical trials
A. Vandamme, R. Schots, Y. Beguin
The Transplantation Committee of the Belgian Hematological Society (BHS) is supported by 
all university centres and nonuniversity centres with significant transplant activity. The 
committee is involved in the development of transplant guidelines and recommendations, 
the transplant peer review process, contacts with regulatory authorities, the introduction of 
expanded access and medical need programs and the initiation of academic studies 
addressing important questions in the transplant field. Since 2008, eight clinical trials have 
been initiated after approval by the Ethics Committees and the National Competent Authority 
(AFMPS/FAGG). So far, one of them has been completed and is being prepared for publication. 
In this paper, we briefly describe the rationale, objectives, treatment arms, major inclusion 
criteria and current status of these different trials. In addition and for each trial a link is 
provided to the BHS website to obtain more details regarding inclusion criteria, participating 
centres and administrative/contact information.
(Belg J Hematol 2012;3:62-67)
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lular therapeutic interventions. The Transplantation 
Committee of the Belgian Hematological Society 
(BHS) has initiated a number of studies related to 
these issues.
1. Trials related to the conditioning re-
gimen 
1.1. Allogeneic haematopoietic cell trans-
plantation with HLA-matched donors: 
a phase II randomised study comparing 
two nonmyeloablative conditionings 
(http://www.bhs.be/frontend/files/ 
userfiles/files/Trials/TC01.pdf)
Alloreactivity of donor immune cells or the GVT ef-
fect plays an important role in eradicating residual 
malignant cells after alloSCT. This prompted the de-
velopment of NM-alloSCT in which the burden for 
engraftment and tumor eradication is shifted from 
high-dose chemo-radiotherapy towards GVT effects. 
The Seattle team has developed a regimen of low-do-
se TBI (2 Gy) and fludarabine (90 mg/m²), followed 
by immunosuppression with mycophenolate mofe-
til (MMF) and cyclosporine (CSP).1 In this setting, 
acute GVHD has no impact on the risk of relapse/
progression, but is associated with non-relapse mor-
tality and decreased progression-free survival (PFS), 
while extensive chronic GVHD is associated with 
a decreased risk of relapse/progression and impro-
ved PFS.2 The Stanford group has developed ano-
ther nonmyeloablative regimen of total lymphoid 
irradiation (TLI; 8 Gy) and ATG (Thymoglobulin, 
7.5 mg/kg), and postgrafting immunosuppression 
with MMF and cyclosporine.3 This regimen favors 
the presence of NK-T regulatory cells and is associa-
ted with a very low incidence of acute GVHD, while 
preserving GVT effects.
In our study, we aimed at comparing the FLU-TBI 
and TLI-ATG regimens for the primary endpoint of 
grade II-IV acute GVHD. The trial started in January 
2008 and recruitment was stopped in January 2011 
(one year ahead of schedule) after 100 patients had 
been included. The results of the interim analysis 
planned after including 60 patients have been pre-
sented at the annual meeting of the BHS in 2011. 
A preliminary analysis of the sub-study investiga-
ting immune reconstitution in the two groups of 
patients (those conditioned with Fluda-TBI versus 
those receiving TLI-ATG) has also been presented at 
the same meeting. Final analysis of the trial is being 
carried out.
1.2. Busulfan dosage in allogeneic stem 
cell transplant recipients receiving 
PO Busulfan containing conditioning 
regimens (http://www.bhs.be/frontend/
files/userfiles/files/Trials/TC08.pdf)
High-dose conditioning regimens containing busul-
fan may be associated with severe organ toxicities, 
including veno-occlusive disease of the liver. Ab-
sorption of oral busulfan is highly variable, leading 
to unpredictable patient exposure. There are three 
main reasons for busulfan dosing and dose adjust-
ment. First, one could reduce toxicity by avoiding 
excessive exposure to the drug, second, one could 
ensure adequate levels to decrease the incidence of 
relapse and graft failure, and third, one could aim 
at obtaining more comparable steady state levels 
in all patients. Therefore, therapeutic drug monito-
ring seems important to achieve maximal systemic 
busulfan exposure while minimising toxicity. 
The BHS Transplant Committee decided to run a 
small non-interventional study, in which the feasi-
bility and validity of the BU dosing method will be 
examined in patients receiving an oral busulfan-con-
taining conditioning regimen. The Ghent University 
Hospital has set up the study for twenty patients in 
Belgium. Busulfan levels are determined in consecu-
tive plasma samples after the first dose administrati-
on, so that, based on the area under the curve (AUC), 
physicians may decide whether to modify BU doses 
on following days. The study should start in 2012.
2. Trials involving the use of mesen-
chymal cell infusions
2.1 Infusion of mesenchymal stem 
cells as treatment for steroid resistant 
grade II to IV acute GVHD or poor graft 
function: a multicentre phase II study 
(http://www.bhs.be/frontend/files/
userfiles/files/Trials/TC02.pdf)
Mesenchymal stem cells (MSC) are stem cells that 
normally give rise to bone, cartilage and fat, but also 
have immunosuppressive properties.4 MSC can be 
cultured from the bone marrow of normal volun-
teers, do not need to be HLA-matched with the pa-
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tient and can be injected intravenously without sig-
nificant side effects. Acute GVHD is a redoubtable 
complication of alloSCT. Its treatment consists in 
high-dose steroids that produce sustained responses 
in only 25-50% of patients. In patients not respon-
ding to steroids, outcome is dismal whatever second 
line therapy is used. Le Blanc et al. have recently de-
monstrated that infusion of third party MSC could 
be successfully used as treatment of grade III-IV, 
steroid-refractory, acute GVHD.5 We aimed at inves-
tigating this in a Belgian multicentre setting.
Poor graft function occurs in 5-25% of patients after 
alloSCT and is associated with consequent morbi-
dity and mortality due to infections and hemorr-
hagic complications. G-CSF may be considered for 
neutropenia and erythropoietin for anemia, second 
alloSCT is associated with high mortality, and a 
boost of CD34-selected PBSC can be proposed to 
selected patients. Small studies have suggested that 
MSC might help improving hematopoiesis in this 
setting.6 We aimed at investigating this in a larger 
number of patients.
Low donor T-cell chimerism is associated with a 
high risk of graft rejection after nonmyeloablative 
alloSCT and donor lymphocyte infusions (DLI) are 
not very efficient in this setting. Animal studies have 
shown that MSC could help sustain engraftment.7 
We postulated that MSC given before DLI might be 
able to prevent graft rejection by decreasing/inhibi-
ting host-versus-graft reactions. 
The trial started in January 2008 with the aim of 
including 100 patients (40 for steroid-refractory 
GVHD, 40 for poor graft function and 20 for poor 
chimerism) and 72 patients have been included so 
far. The results in the first 20 patients with refractory 
acute GVHD were disappointing, so a second co-
hort was opened at a higher dose level. The results 
in patients with poor graft function will be analysed 
before the end of 2012 and recruitment is conti-
nuing in the low chimerism setting.
2.2. Co-transplantation of mesenchy-
mal stem cells and HLA-mismatched 
allogeneic haematopoietic cells af-
ter nonmyeloablative conditioning: a 
phase II randomised double-blind study 
(http://www.bhs.be/frontend/files/
userfiles/files/Trials/TC03.pdf)
Mismatched unrelated donor alloSCT is associated 
with increased GVHD-related mortality and decre-
ased survival. In an attempt to decrease this risk, we 
conducted a pilot study investigating the potential 
of third-party MSC to better prevent GVHD when 
co-infused into 20 patients undergoing NM-alloSCT 
from mismatched unrelated donors.8 Projected 1-yr 
OS and PFS were 80% and 60%, respectively. These 
results compared favorably with those of a histori-
cal group of patients not given MSC for OS (44%, 
P=0.02) as well as PFS (38%, P=0.2). 
We initiated a prospective, multicentre, randomised, 
double-blind, placebo-controlled clinical study ai-
ming at evaluating whether an intravenous injection 
of MSC could improve one-year overall survival in 
patients receiving MSC compared to patients recei-
ving placebo at the time of NM-alloSCT from a par-
tially compatible donor. The aim is to include 120 
patients.
2.3 A pilot study to assess the feasibi-
lity of unrelated umbilical cord blood 
transplantation with coinfusion of third-
party mesenchymal stem cells after 
myeloablative or nonmyeloablative con-




Cord blood (CB) transplantation is increasingly used 
in patients who lack a suitable family or unrelated 
donor, both after myeloablative or nonmyeloablative 
conditioning.9,10 Whereas CB transplantation is ge-
nerally associated with lower risks of severe GVHD 
that transplantation from adult donors, the risk of 
poor engraftment or graft rejection is increased. In 
small series of patients, MSC have been suggested to 
decrease the risk of graft failure after haplo-identical 
transplantation and have been safely infused in reci-
pients of cord blood transplants.11,12 
We designed a single arm study to investigate the 
safety and feasibility of MSC co-infusion at the time 
of CB infusion in adults undergoing myeloablative 
or NM-alloSCT. The aim is to include 20 patients 
in this small pilot study but recruitment has been 
slow so far.
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2.4 Randomized double-blind study of 
mesenchymal stem cells (MSC) in pa-
tients undergoing matched unrelated 
allogeneic bone marrow or peripheral 
blood stem cell transplantation - A Eu-
ropean multicentre study (http://www.
bhs.be/frontend/files/userfiles/files/
Trials/TC05.pdf)
Myeloablative alloSCT from unrelated donor perip-
heral blood stem cell transplantation is associated 
with a high risk of acute and chronic GVHD. Laza-
rus reported rapid hematopoietic recovery and a low 
incidence of GVHD in 46 patients cotransplanted 
with culture-expanded MSC and HSC from HLA-
identical sibling donors after myeloablative conditi-
oning, but this has not been studied in alloSCT with 
unrelated donors.13 
Within the Stem Cell Subcommittee of the Euro-
pean Group for Blood and Marrow Transplantation 
(EBMT), K LeBlanc initiated a prospective, ran-
domised, double-blind, placebo-controlled study 
comparing alloSCT from unrelated donors, with or 
without a co-infusion of third party MSC. The aim is 
to include 172 patients. The primary outcome mea-
sures are the cumulative incidences of grade II-IV 
acute GVHD and of extensive chronic GVHD. The 
CHU of Liège started the study in 2010 and other 
Belgian centres joined in 2011.
3. Trials related to the posttransplant 
immunosuppression
3.1 Prevention and treatment of severe 
GVHD after allogeneic haematopoie-
tic stem cell transplantation, applied 
as consolidation immunotherapy in 
patients with haematological malignan-
cies. A prospective randomised phase 
III trial (http://www.bhs.be/frontend/fi-
les/userfiles/files/Trials/TC06.pdf).
After alloSCT, GVT effects significantly reduce the 
rate of leukaemic relapse. This immunotherapeutic 
effect is strongly associated with the occurrence of 
acute and/or chronic GVHD but patients with se-
vere GVHD experience excess mortality. Different 
immunosuppressive regimens are used in order to 
prevent GVHD, but the optimal duration of GVHD 
prevention is not known. 
The HOVON group decided to initiate an interna-
tional collaborative study in HLA-id sibling mye-
loablative transplantation, in which two preventive 
regimens combining MMF and cyclosporine are 
prospectively compared, i.e. a time-restricted im-
munosuppressive regimen (MMF for 28 days and 
cyclosporine for 84 days) and a prolonged regimen 
(MMF for 84 days and cyclosporine for 180 days). 
In patients with steroid-refractory acute GVHD, an-
ti-thymocyte globulin (ATG) is frequently applied. 
The study initially proposed to introduce ATG toge-
ther with steroids in first line therapy for very severe 
acute GVHD, but this randomisation was closed for 
lack of accrual.
3.2. Allogeneic haematopoietic cell 
transplantation from HLA-matched 
donors after reduced-intensity condi-
tioning : a phase II randomised study 
comparing two GVHD prophylaxis re-
gimen (http://www.bhs.be/frontend/
files/userfiles/files/Trials/TC07.pdf)
Sirolimus (rapamycin) is a naturally occurring macro-
lide with antineoplastic and immunosuppressive pro-
perties, that is active in the prevention and treatment 
of acute and chronic GVHD, perhaps by preserving 
regulatory T-cells while inhibiting effector T cell pro-
liferation and activation. The addition of sirolimus to 
tacrolimus or MMF in patients undergoing unrelated 
HLA-matched alloSCT after Fludarabine-TBI resulted 
in a lower incidence of grades II-IV acute GVHD, but 
not chronic GVHD. In a retrospective analysis of 190 
patients undergoing alloSCT for lymphoma, overall 
survival was significantly superior in patients recei-
ving sirolimus compared to those receiving a calci-
neurin inhibitor plus methotrexate.14 Non-relapse 
mortality was similar, while disease progression and 
grade II-IV acute GVHD (but not of chronic GVHD) 
were decreased, but the benefit was restricted to pa-
tients undergoing reduced-intensity conditioning. 
After completing TC-01, the BHS Transplant Com-
mittee thus decided for its next NM-alloSCT pro-
tocol in 10/10 matched related or unrelated donor 
transplantation, to undergo a prospective compari-
son between two GVHD prevention regimens, i.e. 
the classical tacrolimus + MMF combination versus 
a tacrolimus + sirolimus combination. The aim is 
to include 200 patients and the trial started at the 
end of 2011.
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4. Cell therapy trials
Wilms’ tumor (WT1) antigen-targeted 
dendritic cell vaccination to prevent 
relapse in patients older than 65 years 
with acute myeloid leukemia : a multi-
centre randomised phase II trial (http://
www.bhs.be/frontend/files/userfiles/
files/Trials/TC09.pdf) 
The prognosis of elderly patients with acute my-
eloid leukaemia (AML) remains dismal, as up to 
80% of these patients will eventually relapse, due 
to a small reservoir of resistant AML stem cells per-
sisting after chemotherapy. For patients ineligible 
for alloSCT, there is no standard post-remission 
therapy to avoid relapse. Immunotherapy has 
come to the fore in recent years. The concept of 
vaccination is based on the observation that AML 
cells carry leukaemia-associated antigens (LAA), 
allowing their recognition and elimination by LAA-
specific cytotoxic T lymphocytes (CTLs). Dendritic 
cells (DC) are the most effective antigen-presen-
ting cells and tumor antigen-loaded DCs are an at-
tractive tool for activating tumor-specific immune 
response in cancer patients. The Antwerp group 
has recently reported encouraging results from an 
open-label phase I/II clinical trial of DC-based vac-
cination in the AML post-remission setting, using 
autologous DC loaded with the LAA Wilms’ tumor 
protein 1 (WT1) through mRNA electroporation.15 
WT1 is a tumor-associated antigen that is highly 
overexpressed in several malignancies, including 
AML, and is also present in leukemic stem cells. 
In the first cohort of 17 evaluable patients, they 
observed a decrease to normal of WT1 transcript 
levels in eight patients.16 Median DFS and OS 
have not been reached for those eight responding 
patients, whereas in the other nine patients they 
were only 2.7 months and 5.5 months, respecti-
vely. These results support a DC vaccine strategy to 
eradicate leukaemia and prevent relapse in elderly 
AML patients. 
Upon a study proposal of the Antwerp group, the 
BHS Transplant Committee agreed to support a 
randomised study in a larger, multicentre cohort of 
patients (n=138). The study will be started later 
in 2012 after approval by the regulatory authori-
ties and securing a grant from the national Cancer 
Plan.
Conclusion
The Transplantation Committee of the Belgian He-
matological Society (BHS) has initiated several aca-
demic clinical trials addressing important questions 
related to the field of allogeneic stem cell transplan-
tation. These efforts have led to a close collaboration 
between Belgian transplant centres that thus far was 
unprecedented and benefits progress in science as 
well as daily care for our transplant patients.
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